Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284613 | 0.88 | GPR119 (0.53) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL19297043 | 0.86 | GPR119 (0.52) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL19284639 | 0.86 | GPR119 (0.52) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL19297082 | 0.86 | GPR119 (0.49) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL19284622 | 0.85 | STS (0.53) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL19297150 | 0.85 | GPR119 (0.51) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL23443529 | 0.85 | GPR119 (0.53) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL30368880 | 0.85 | GPR119 (0.53) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL19284638 | 0.85 | CCR8 (0.49) | GPR119NAMPTKDM4ETHRBMAPT | |
| SCHEMBL30534946 | 0.85 | GPR119 (0.55) | GPR119NAMPTKDM4ETHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | SRX CARDIO, LLC | 2021-02-04 | — | — | US | disclosed |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2019-04-25 | — | — | US | disclosed |
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| EP-2331526-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-06-15 | — | — | EP | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| WO-2009158431-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158431-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | GPR119 405/4885NAMPT 1241/4885KDM4E 2393/4885 |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | PCSK9, PCSK6, PCSK7 | GPR119 567/4885NAMPT 1061/4885KDM4E 2046/4885 |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | GPR119 545/4885NAMPT 1105/4885KDM4E 2446/4885 |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | GPR119 36/4885NAMPT 1084/4885KDM4E 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.